Abstract
Since 1999, the funding available for the control of diseases of poverty (neglected diseases) has increased mainly due to leverage resulting from donations by the Bill and Melinda Gates Foundation and loans from the World Bank. Many countries have embarked on control programmes on a national scale due to drug donations by pharmaceutical companies through vertical programmes. The Schistosomiasis Control Initiative has expanded its operations to cover six countries in sub-Saharan Africa, but overlap of treatments between different vertical programmes is now a reality, and so care is needed to ensure that too many different drugs are not given together. Dialogue between programme managers has increased, and integration of some programmes may offer chances of synergy.
TY - JOUR
T1 - New initiatives against Africa's worms.
A1 - Fenwick,Alan,
Y1 - 2005/12/15/
PY - 2004/12/20/received
PY - 2005/02/15/revised
PY - 2005/03/09/accepted
PY - 2005/12/14/pubmed
PY - 2006/7/18/medline
PY - 2005/12/14/entrez
SP - 200
EP - 7
JF - Transactions of the Royal Society of Tropical Medicine and Hygiene
JO - Trans R Soc Trop Med Hyg
VL - 100
IS - 3
N2 - Since 1999, the funding available for the control of diseases of poverty (neglected diseases) has increased mainly due to leverage resulting from donations by the Bill and Melinda Gates Foundation and loans from the World Bank. Many countries have embarked on control programmes on a national scale due to drug donations by pharmaceutical companies through vertical programmes. The Schistosomiasis Control Initiative has expanded its operations to cover six countries in sub-Saharan Africa, but overlap of treatments between different vertical programmes is now a reality, and so care is needed to ensure that too many different drugs are not given together. Dialogue between programme managers has increased, and integration of some programmes may offer chances of synergy.
SN - 0035-9203
UR - https://www.unboundmedicine.com/medline/citation/16343572/New_initiatives_against_Africa's_worms_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0035-9203(05)00339-1
DB - PRIME
DP - Unbound Medicine
ER -